Carregant...
Fitxers
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/218503
A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
CD19-directed chimeric antigen receptor (CAR) T cells have yielded impressive response rates in refractory/relapse B cell acute lymphoblastic leukemia (B-ALL); however, most patients ultimately relapse due to poor CAR T cell persistence or resistance of either CD19+ or CD19- B-ALL clones. CD22 is a pan-B marker whose expression is maintained in both CD19+ and CD19- relapses. CD22-CAR T cells have been clinically used in B-ALL patients, although relapse also occurs. T cells engineered with a tandem CAR (Tan-CAR) containing in a single construct both CD19 and CD22 scFvs may be advantageous in achieving higher remission rates and/or preventing antigen loss. We have generated and functionally validated using cutting-edge assays a 4-1BB-based CD22/CD19 Tan-CAR using in-house-developed novel CD19 and CD22 scFvs. Tan-CAR-expressing T cells showed similar in vitro expansion to CD19-CAR T cells with no increase in tonic signaling. CRISPR-Cas9-edited B-ALL cells confirmed the bispecificity of the Tan-CAR. Tan-CAR was as efficient as CD19-CAR in vitro and in vivo using B-ALL cell lines, patient samples, and patient-derived xenografts (PDXs). Strikingly, the robust antileukemic activity of the Tan-CAR was slightly more effective in controlling the disease in long-term follow-up PDX models. This Tan-CAR construct warrants a clinical appraisal to test whether simultaneous targeting of CD19 and CD22 enhances leukemia eradication and reduces/delays relapse rates and antigen loss.
Matèries
Matèries (anglès)
Citació
Citació
ROMECÍN, Paola alejandra, ZANETTI, Samanta romina, VELASCO-HERNANDEZ, Talia, GUTIERREZ-AGÜERA, Francisco, DÍAZ, Víctor m., ROCA-HO, Heleia, SÁNCHEZ-MARTÍNEZ, Diego, TIRADO CABRERA, Néstor, BARONI, Matteo libero, PETAZZI, Paolo, TORRES-RUIZ, Raúl, MOLINA, Òscar, BATALLER TORRALBA, Alex, FUSTER, José luis, BALLERINI, Paola, JUAN, Manel, JEREMIAS, Irmela, BUENO, Clara, MENÉNDEZ, Pablo. A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL. _Molecular Therapy_. 2022. Vol. 30, núm. 2, pàgs. 550-563. [consulta: 20 de gener de 2026]. ISSN: 1525-0016. [Disponible a: https://hdl.handle.net/2445/218503]